Abstract ISI
JOURNAL OF CLINICAL ONCOLOGY  (2024)

Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair-deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study

Rojas C.; Eskens F.; Ghiringhelli F.; Özgüroglu, M; Caglevic C.; Gumus M.; Tosi D.; Grenier J.; González Á.F.; Arenas A.; Gonzalez-Cortijo L.; Robinson A.G.; Cuello J.; Bell M.C.; Kwiatkowski M.; et. al.